Response to Gungor et al. Regarding Morishita et al., “Association of Quinolone Exposure in the First Trimester of Pregnancy and the Risk of Major Congenital Malformations: A Health Administrative Database Study in Japan”
Kei Morishita, Takamasa Sakai, Taku Obara. Response to Gungor et al. Regarding Morishita et al., “Association of Quinolone Exposure in the First Trimester of Pregnancy and the Risk of Major Congenital Malformations: A Health Administrative Database Study in Japan”. // Pharmacoepidemiology and Drug Safety. – 2026. – DOI: 10.1002/pds.70524. – URL: https://onlinelibrary.wiley.com/doi/10.1002/pds.70524?af=R
Kei Morishita, Takamasa Sakai, & Taku Obara (2026). Response to Gungor et al. Regarding Morishita et al., “Association of Quinolone Exposure in the First Trimester of Pregnancy and the Risk of Major Congenital Malformations: A Health Administrative Database Study in Japan”. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70524
Kei Morishita, et al. “Response to Gungor et al. Regarding Morishita et al., “Association of Quinolone Exposure in the First Trimester of Pregnancy and the Risk of Major Congenital Malformations: A Health Administrative Database Study in Japan”.” Pharmacoepidemiology and Drug Safety, 2026. doi:10.1002/pds.70524.
@article{Morishita2026,
title = {Response to Gungor et al. Regarding Morishita et al., “Association of Quinolone Exposure in the First Trimester of Pregnancy and the Risk of Major Congenital Malformations: A Health Administrative Database Study in Japan”},
author = {Morishita, Kei and Sakai, Takamasa and Obara, Taku},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2026},
doi = {10.1002/pds.70524},
url = {https://onlinelibrary.wiley.com/doi/10.1002/pds.70524?af=R}
}